Thomas A. Lagace, Ph.D.
Affiliations: | 2004 | Dalhousie University, Halifax, Nova Scotia, Canada |
Area:
Molecular BiologyGoogle:
"Thomas Lagace"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Neale Ridgway | grad student | 2004 | Dalhousie University | |
| (Regulation of phosphatidylcholine synthesis by cellular metabolites and enzyme localization.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rasheed A, Robichaud S, Nguyen MA, et al. (2020) Loss of MLKL (Mixed Lineage Kinase-Like Domain Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. ATVBAHA119313640 |
| Sarkar SK, Foo ACY, Matyas A, et al. (2020) A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles. The Journal of Biological Chemistry |
| Lagace TA. (2015) Phosphatidylcholine: Greasing the Cholesterol Transport Machinery. Lipid Insights. 8: 65-73 |
| Alghamdi RH, O'Reilly P, Lu C, et al. (2015) LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation. European Journal of Medicinal Chemistry. 92: 890-907 |
| Lagace TA. (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Current Opinion in Lipidology. 25: 387-93 |
| Nguyen MA, Kosenko T, Lagace TA. (2014) Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. Journal of Lipid Research. 55: 266-75 |
| Lagace TA, Ridgway ND. (2013) The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochimica Et Biophysica Acta. 1833: 2499-510 |
| Kosenko T, Golder M, Leblond G, et al. (2013) Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. The Journal of Biological Chemistry. 288: 8279-88 |
| Lakoski SG, Lagace TA, Cohen JC, et al. (2009) Genetic and metabolic determinants of plasma PCSK9 levels. The Journal of Clinical Endocrinology and Metabolism. 94: 2537-43 |
| McNutt MC, Kwon HJ, Chen C, et al. (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. The Journal of Biological Chemistry. 284: 10561-70 |